| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Global X S&P Biotech ETF Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$48.46 |
| 52 Week High | AU$54.00 |
| 52 Week Low | AU$34.75 |
| Beta | 0 |
| 11 Month Change | -3.79% |
| 3 Month Change | 1.13% |
| 1 Year Change | 24.03% |
| 33 Year Change | -18.50% |
| 5 Year Change | 0.75% |
| Change since IPO | -1.08% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CURE | AU Capital Markets | AU Market | |
|---|---|---|---|
| 7D | -5.6% | 1.7% | 0.3% |
| 1Y | 24.0% | 31.5% | 16.1% |
Return vs Industry: CURE underperformed the Australian Capital Markets industry which returned 31.5% over the past year.
Return vs Market: CURE exceeded the Australian Market which returned 16.1% over the past year.
Price Volatility
| CURE volatility | |
|---|---|
| CURE Average Weekly Movement | 3.6% |
| Capital Markets Industry Average Movement | 4.6% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: CURE has not had significant price volatility in the past 3 months.
Volatility Over Time: CURE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.etfsecurities.com.au |
Global X S&P Biotech ETF Fundamentals Summary
| CURE fundamental statistics | |
|---|---|
| Market cap | n/a |
| Earnings (TTM) | AU$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CURE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURE income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$0 |
| Other Expenses | AU$0 |
| Earnings | AU$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CURE perform over the long term?
See historical performance and comparison